arrow
R

Radka Obermannová

Masaryk University
H指数:29
被引数:5,731

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression-Free Survival as a surrogate for Overall Survival in gastro-esophageal cancer trials with immunotherapy: a meta-analysis

无进展生存期作为免疫治疗在胃肠癌临床试验中总体生存期的替代指标:一项荟萃分析

2025-11-290
OAAI
Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial

实体肿瘤患者接受BNT162b2 COVID-19疫苗基础免疫后,主动治疗情况下SARS-CoV-2特异性体液和细胞免疫应答模式:CoVigi IV期试验结果

2025-05-170
OA
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypND and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

术前化疗后复发风险高的胃和食管胃交界癌患者的辅助免疫治疗 (ypND和/或R1): 欧洲癌症研究与治疗组织 (EORTC) 1707痕迹研究

2025-02-013
OAAI
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

欧洲寡转移食管胃癌的定义、诊断和治疗临床实践指南 (OMEC-4)

2024-06-014
OAAI
EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)-an open-label randomized controlled phase II study
2023-06-017
OAAI
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
2023-06-0162
OAAI
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

寡转移食管胃癌的定义,诊断和治疗: 欧洲的Delphi共识研究

2023-05-0122
OA
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
2022-10-0118
OAAI